Key information

🔎 Fund Overview

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.